Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. is a drug discovery company that focuses on developing novel psychedelic and non-psychedelic medications to address neuropsychiatric and neurological disorders with unmet medical needs. The company recently entered into a definitive arrangement agreement with Otsuka Pharmaceutical Co., Ltd., signaling a significant acquisition worth approximately CAD $80 million. Mindset's innovative compounds and synthesis processes aim to revolutionize the treatment of psychiatric disorders, contributing to patient care on a global scale.
The Transaction, expected to close in October 2023, marks a strategic move by Otsuka to strengthen its presence in the psychiatry and neurology therapeutic areas. Mindset's shareholders will benefit from the all-cash acquisition, demonstrating a premium value of $0.75 per share. With a focus on maximizing the value of its assets and IP portfolio, Mindset's collaboration with Otsuka is poised to lead to groundbreaking advancements in patient treatment.
In pursuit of its mission to develop next-generation pharmaceutical assets, Mindset is dedicated to creating optimized and patentable psychedelic medicines, leveraging the therapeutic potential of psychedelic drugs. Through proprietary compounds, novel families of psychedelic compounds, and innovative synthesis processes, the company is at the forefront of advancing treatment options for neurological and psychiatric conditions.
Mindset Pharma (CSE: MSET, OTCQB: MSSTF) has announced the synthesis of new candidates from its Family 3 drug portfolio, initiating upcoming Proof of Concept preclinical studies. CEO James Lanthier highlighted that these compounds aim to demonstrate pro-cognitive benefits without inducing psychedelic effects, targeting markets such as juvenile ADHD and Alzheimer's. The Company also has a co-development agreement with McQuade Center, advancing its Family 2 & 4 compounds, indicating a commitment to addressing unmet medical needs in neurology and psychiatry, potentially broadening its market reach.
Mindset Pharma Inc. (OTCQB: MSSTF) has appointed Dr. Fiona Randall as the new Senior Vice President of External Alliances and Scientific Strategy. Dr. Randall, a trained neuroscientist, brings extensive experience in neurological research and alliance management. Her previous roles include founding FireWire Consulting and leading strategic partnerships at Vertex Pharmaceuticals and Eisai. CEO James Lanthier noted that her expertise will accelerate Mindset's growth in developing next-generation psychedelic medicines aimed at treating neurological and psychiatric disorders.
Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) has announced the synthesis of new candidates from its Family 3 of next-generation psilocybin compounds, which exhibit low activity at the 5-HT2A receptor and significant half-lives. The Company plans to initiate Proof of Concept preclinical studies to evaluate these compounds as daily pro-cognitive medications for neurological and psychiatric disorders. CEO James Lanthier highlighted the potential to address markets like juvenile ADHD and Alzheimer's without the hallucinogenic effects of traditional psychedelics. Mindset also recently secured a co-development agreement with Otsuka Pharmaceuticals.
Mindset Pharma (MSSTF) recently announced a significant collaboration with The McQuade Center for Strategic Research, part of the Otsuka group, to develop psychedelic medicines targeting neurological and psychiatric disorders. This partnership highlights Mindset's commitment to creating innovative treatments for mental illness. CEO James Lanthier emphasized plans to initiate clinical trials soon, marking an essential step in drug development. The relationship with Otsuka, which generated USD 13.3 billion in sales in 2020, could enhance Mindset's capabilities in clinical research and product commercialization.
Mindset Pharma has entered a manufacturing agreement with a leading CDMO for its psilocybin drug candidate, MSP-1014. This partnership aims to produce pharmaceutical-grade batches and position MSP-1014 for clinical trials. CEO James Lanthier highlighted the compound's improved efficacy and safety over first-generation psilocybin, along with its potential for both clinical and home use. MSP-1014, not classified as a scheduled substance, is expected to have a more efficient manufacturing process, enhancing its commercialization prospects.
Mindset Pharma (OTCQB: MSSTF) announced participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO James Lanthier's corporate presentation will be available on-demand starting January 10 at 7:00 a.m. ET. The company has engaged Emerging Markets Consulting for investor relations, with a 12-month contract worth USD $250,000. Mindset specializes in developing next-generation psychedelic medicines aimed at treating neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced significant strides in 2021, focusing on developing next-generation psychedelic medicines for neurological and psychiatric disorders. The company advanced its lead clinical candidate, MSP-1014, towards IND-enabling studies. Mindset filed four provisional patents, expanding its portfolio to eight. The firm synthesized over 100 novel compounds, attained safety and efficacy benchmarks, and strengthened its leadership team.
Mindset Pharma Inc. (OTCQB: MSSTF) has filed an international patent application for its Family 3 psychedelic compounds, which show extended half-lives compared to traditional psychedelics. These compounds are believed to provide pro-cognitive benefits without hallucinogenic effects, making them suitable for vulnerable groups like children and the elderly. The priority date for this application is based on a prior provisional filing on December 7, 2020. Additionally, the company granted options to purchase 500,000 shares at $0.69 each, subject to a four-month hold period.
Mindset Pharma (OTCQB: MSSTF), a drug discovery company focused on developing next-generation psychedelic medicines, will participate in the Citi Psychedelic Drug Call Series on January 6, 2022. CEO James Lanthier and CSO Joseph Araujo will engage in a fireside chat. Additionally, the team will attend the 40th Annual J.P. Morgan Healthcare Conference from January 10-12, 2022, in San Francisco. Mindset is dedicated to addressing neurological and psychiatric disorders through innovative psychedelic compounds.
Mindset Pharma is set to participate in Stifel GMP’s Future of Healthcare Conference on December 8, 2021. The company focuses on developing next-generation psychedelic medicines designed to address significant neurological and psychiatric disorders. CEO James Lanthier and CSO Joseph Araujo will present live at 1:00 p.m. ET. Interested parties can register for the event through the company's website. Mindset is exploring novel psychedelic compounds and processes, including the synthesis of psilocybin, to fulfill unmet medical needs.
FAQ
What is the market cap of Mindset Pharma (MSSTF)?
What is Mindset Pharma Inc. focused on?
What recent agreement did Mindset Pharma Inc. enter into?
How will the acquisition benefit Mindset Pharma Inc.'s shareholders?
What is the focus of Mindset Pharma Inc.'s drug development programs?
What is the expected timeline for the completion of the Transaction between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.?
How does the collaboration between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd. contribute to patient care?
What sets Mindset Pharma Inc. apart in the pharmaceutical industry?
